Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
770
0
7

Year Published

2010
2010
2016
2016

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 1,524 publications
(781 citation statements)
references
References 128 publications
4
770
0
7
Order By: Relevance
“…Addressing the biocompatibility of drug carriers is a major issue in developing drug delivery systems (Gaspar and Duncan, 2009;Liu et al, 2008;Rodrigues et al, 2012a) and current international guidelines require the contextualisation of biocompatibility with a specific route of administration and dose of the material (Gaspar and Duncan, 2009). In turn, it is also mandatory to treat polymers and polymer-based carriers as different entities, as the proper carrier structure, among other parameters, might affect the final behaviour (Aillon et al, 2009;Gaspar and Duncan, 2009;Williams, 2008).…”
Section: In Vitro Cytotoxicity Study Of Pullulan-based Nanoparticlesmentioning
confidence: 99%
See 2 more Smart Citations
“…Addressing the biocompatibility of drug carriers is a major issue in developing drug delivery systems (Gaspar and Duncan, 2009;Liu et al, 2008;Rodrigues et al, 2012a) and current international guidelines require the contextualisation of biocompatibility with a specific route of administration and dose of the material (Gaspar and Duncan, 2009). In turn, it is also mandatory to treat polymers and polymer-based carriers as different entities, as the proper carrier structure, among other parameters, might affect the final behaviour (Aillon et al, 2009;Gaspar and Duncan, 2009;Williams, 2008).…”
Section: In Vitro Cytotoxicity Study Of Pullulan-based Nanoparticlesmentioning
confidence: 99%
“…Nanoparticles have been proposed as suitable protein carriers, overcoming many of the limitations posed by the physicochemical characteristics of these macromolecules, which are very susceptible to degradation and undergo difficult absorption due to their size and, usually, hydrophilicity (Antosova et al, 2009;Liu et al, 2008). Nanoparticles potentiate the improvement of drug pharmacokinetic profile, not only by providing their stabilisation but, in some cases, also permitting controlled release and enhancing drug absorption (Grenha, 2012;Hartig et al, 2007).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…For these reasons, polysaccharides and their derivatives are widely used in a large number of industries, including the pharmaceutical industry. For these reasons, the encapsulation of active compounds in polysaccharide-based microparticles has been the subject of great interest [51]. In our research group, we have already encapsulated several active compounds in microparticles obtained from different polysaccharides, using several microparticle preparation techniques.…”
Section: Polysaccharidesmentioning
confidence: 99%
“…Also, it is reported that the circulation halftime of drugs is improved and protected from inactivity during blood circulation and transport to the specific tissue (Peres et al 2012;Liu et al 2012;Ruíz-Ramos et al 2006;Goodarzi et al 2013;Iyer et al 2006;Nam et al 2009;Yousefpour et al 2011). Moreover, the nanoparticles are biocompatible, stable and in vitro non-toxic (Liu et al 2008;Gomes et al 2010). The control of charged surfaces allows interactions with negatively charged components from plasma membrane and, therefore, internalized into cells by endocytosis (Beija et al 2012;Gratton et al 2008).…”
Section: Introductionmentioning
confidence: 99%